Status update on clinical trial for the treatment of relapsed prostate cancer patients
The pandemic has led to a significant slowdown in SpectraCure's clinical activities. Several hospitals suspended the conduct of studies for an extended period of time and SpectraCure staff have been prevented from travelling due to travel bans in the countries where the study is being conducted. The clinical study protocol involves a number of follow-up […]
Investor Letter July 2021
Ingemar Kihlström, Chairman of the Board, and Johan Folkunger, CEO, reflect on a strong commitment and combined expertise and Homer Pien, recently appointed Board member of SpectraCure, is introduced. Investor letter July 2021 is attached. For further information, please contact: Johan Folkunger, SpectraCures CEO, e-mail: jf@spectracure.com Please also visit, www.spectracure.com SpectraCure is developing a treatment […]
The Nomination Committee’s proposal for election of board members in SpectraCure AB
The Nomination Committee has decided to propose the re-election of Board members Ingemar Kihlström, Katarina Svanberg, Sune Svanberg, Ulf Bladin and Hans Bornemark at the Annual General Meeting of SpectraCure AB (publ) on Tuesday 18 May 2021. Ingemar Kihlström is proposed for re-election as Chairman of the Board. Masoud Khayyami, current Board Member, has declined […]
Johan Folkunger appointed new CEO of SpectraCure AB
The Board of Directors of SpectraCure has appointed Johan Folkunger new CEO, with a clear mandate to prepare and lead the Company into the next phase, commercialization. Johan Folkunger has held senior positions in a number of life science and medical technology companies, most recently as responsible for the Medical Technology business area at the […]
Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
Following the discussions at Investigator Meetings during November 2020 – February 2021, in which doctors and representatives of the clinics included in the company's clinical study participated, a status update follows in light of the current pandemic. Participating hospitals are University College London Hospital, Princess Margaret Cancer Centre in Toronto, University of Pennsylvania Hospital in […]
Positive discussions at SpectraCure’s Investigator Meeting
SpectraCure has held an Investigator Meeting where the topic of discussion was statistics and results from the treatments conducted in the Company's clinical study. The discussions at the meeting will also form the basis of the forthcoming application for Accelerated Approval. Physicians and representatives of the hospitals included in the study participated in the meeting: […]
Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!
Apply to The European Training Network PHAST (Photonics for Healthcare: multiscAle cancer diagnosiS and Therapy). Maybe you will be one of 15 Early Stage Researchers (ESRs) which will be enrolled in a strong multidisciplinary PhD programme. Position #12 is at SpectraCure Development of advanced online dosimetry algorithms for photodynamic therapy of tumours. Brief description of […]
Wider range of prospective patients in the UK, Canada and the US for continued clinical study
As previously disclosed, the US authority FDA has approved SpectraCure's new and revised study protocol for the clinical study on patients with recurrent prostate cancer. The protocol has also been approved by the UK and Canadian authorities. The new protocol expands the inclusion criteria for Gleason score, which allows a wider range of candidates to […]
A future alternative to hormonal treatment for prostate cancer
At this year's cancer congress in Chicago (ASCO), novel hormone treatments of patients suffering from non-metastatic castration-resistant prostate cancer were recognized. There are currently no efficient treatment options for the condition. Prostate cancer is the most common form of cancer in the western world. Every year, approximately 600,000 new cases are diagnosed in the US […]
Patent application submitted to protect new technology
SpectraCure has submitted a new patent application to the European Patent Office. The patent application regards the technical solution used in the new generation of SpectraCure's treatment system. The technology makes it possible to use the same optical fiber for both treatment and dose monitoring; together with the IDOSE software, this is what makes the […]
